Pyrotech Advances PTT-121 Into Phase 1 Clinical Trial
Beijing, China, September 1, 2026 Pyrotech Therapeutics has announced a major clinical development milestone for PTT-121, an investigational selective...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Beijing, China, September 1, 2026 Pyrotech Therapeutics has announced a major clinical development milestone for PTT-121, an investigational selective...
Columbus, Ohio, September 1, 2026 Andelyn Biosciences has announced that Genprex, Inc. has selected the contract development and manufacturing...
Dublin, Ireland, September 1, 2026 Keenova Therapeutics plc has announced new initiatives for the second annual National Hand Health...
